Search PULM
Pulmatrix, Inc.
Nasdaq · CIK 1574235
Last close1.57
Daily change+0.03 (1.95%)
10 Years gain-99.52%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PULM · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
54.6Momentum
100.0Acceleration
60.0Confidence
88.0Annual Revenue13
Quarterly Revenue36
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.0 / 25
Quality6.5 / 25
Capital Efficiency6.6 / 20
Balance Sheet12.8 / 15
Shareholder Economics7.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 155.6077 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Negative FCF · HIGHLatest free cash flow is negative.
ROIC declining · MEDIUMROIC declined by 35.191 percentage points.
Key Metrics
Revenue Growth TTM45.98%OK
Revenue CAGR 3Y14.73%OK
Gross Margin100%OK
Operating Margin-122.96%OK
FCF Margin-149.73%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-78.71%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO0.79xOK
Diluted Share Growth 1Y0%OK
SBC / Revenue7.37%OK
SBC / FCF-4.92%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $0.00 | -$5.17M | -$5.43M | n/a | n/a | n/a | n/a | n/a | 3.65M |
| 2025 FY Dec 31, 2024 | $7.81M | $7.81M | -$9.76M | -$10.72M | -$11.11M | 100% | -125.07% | -142.38% | n/a | 3.65M |
| 2024 FY Dec 31, 2023 | $7.30M | $7.30M | -$14.74M | -$15.99M | -$16.66M | 100% | -201.97% | -228.3% | n/a | 3.65M |
| 2023 FY Dec 31, 2022 | $6.07M | $6.07M | -$18.95M | -$19.36M | -$19.44M | 100% | -312.09% | -320.24% | n/a | 3.45B |
| 2022 FY Dec 31, 2021 | $5.17M | $5.17M | -$20.17M | -$19.73M | -$19.87M | 100% | -390.15% | -384.43% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $9.56M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-24-044163, 0001641172-25-010533 |
| Revenue Growth TTM | 45.98% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-24-044163, 0001641172-25-010533 |
| Revenue CAGR 3Y | 14.73% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-028902 |
| Revenue CAGR 5Y | -0.26% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-028902 |
| Gross Profit CAGR 3Y | 14.73% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-028902 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-24-044163, 0001641172-25-010533 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-24-044163, 0001493152-24-031478 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001493152-24-044163, 0001641172-25-010533 |
| Operating Margin | -122.96% | Operating Income / Revenue | OK | 0001493152-24-044163, 0001641172-25-010533 |
| FCF Margin | -149.73% | (CFO - CapEx) / Revenue | OK | 0001493152-24-044163, 0001493152-24-031478 |
| ROIC | -78.71% | NOPAT / Average Invested Capital | OK | 0001493152-24-044163, 0001641172-25-010533 |
| Net Debt / CFO | 0.79x | Net Debt / CFO | OK | 0001493152-25-018256, 0001493152-24-044163 |
| Current Ratio | 19.4x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 7.37% | SBC / Revenue | OK | 0001493152-24-044163, 0001493152-24-031478 |